Caplin Point Laboratories Limited

Caplin Point Laboratories reported strong financial results for Q3 FY26, with operating revenue growing by 10.6% Y-o-Y and total income by 11.2% Y-o-Y. The nine-month revenue is now close to the entire FY24 revenue. The company demonstrated improved operational efficiency, with COGS as a percentage of revenue decreasing from 43% to 39% over three years, and Opex growing only 6%, significantly below revenue growth. This led to a 17% growth in EBITDA margin, reaching 38.5% compared to 36.5% in the prior year period. PAT grew 20.5%, with the PAT margin at 28.5%, exceeding the entire FY24 PAT of INR 461 crores.

The US label business has shown significant traction, achieving nearly $10 million in revenue since its inception last year. The company continues to receive consistent approvals from the US, with a complex suspension injectable product (Methylprednisolone) approved in the first cycle, demonstrating approval timelines of 14-15 months, faster than the industry average of 20 months. With 10 products pending FDA review, Caplin Point expects to have around 65 ANDAs approved under its name shortly. Additionally, 14 ANDAs have been acquired and are being actively prepared for market launch in 2026-2027.

Caplin Point is strategically expanding its product pipeline and manufacturing capabilities. The company is focusing on ophthalmic and pre-filled syringe ranges, with 12-13 products expected to be completed in the next 12 months for approval by end of next year. A new blow-fill-seal range is being introduced with an order placed for a state-of-the-art machine, and 14 products are under development, with first approvals anticipated in late FY27-FY28. The Caplin One Lab's unit 2 (Phase 3) facility, designed to house eight product lines, will have five lines active by early next year, with three more completing by September-October this year.

The company is actively pursuing growth in larger Latin American markets like Mexico and Chile. Management expects these markets to start 'firing on all cylinders' in 18-24 months, with a strategic shift towards the private market, moving away from tender-heavy business. In Chile, a revenue potential of $10-$15 million per year is considered possible. For Mexico, the company plans to invest INR 100-125 crores in a facility for ointments and liquid orals, aiming to leverage local industry advantages and high transportation costs for these products.

Caplin Point is innovating its compliance and operational efficiency through initiatives like video SOPs (visual scripts) to convert invisible execution into inspectable evidence, aiming to improve quality and reduce non-compliance. This system will also aid in training new employees and remote monitoring. Furthermore, the company has recruited two former senior inspectors from Colombian INVIMA to enhance audit readiness across all factories, ensuring integrity and quality, especially for the onco facility and CP I which expect INVIMA audits in April.

The company has invested INR 180 crores in capex this quarter, with total capex incurred so far amounting to INR 385 crores (INR 153 crores capitalized, INR 124 crores in WIP, and INR 88.54 crores advanced). The remaining INR 615 crores of the INR 1,000 crores capex plan is expected to be spent in the next 12-18 months. All capital expenditures are being funded through internal accruals, with management emphasizing that no money is borrowed, thus avoiding interest loss. Cash and cash equivalents stood at a healthy INR 1,381 crores.